Attovia director reports indirect preferred holdings
Attovia Therapeutics, Inc. director Colin Walsh reported initial indirect holdings of the company’s preferred stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Attovia Therapeutics, Inc. director Colin Walsh reported initial indirect holdings of the company’s preferred stock. The filing lists Series B Preferred Stock convertible into 1,957,140 shares of common stock and Series C Preferred Stock convertible into 478,501 shares of common stock, all held through Goldman Sachs–affiliated investment vehicles. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
WALSH COLIN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Series B Preferred Stock F1, F2, F3 | -- | -- | -- |
| Holding | Series C Preferred Stock F1, F2, F3 | -- | -- | -- |
Holdings:
Series B Preferred Stock — 1,957,140 contracts (Indirect, See Footnote);
Series C Preferred Stock — 478,501 contracts (Indirect, See Footnote)
Footnotes (3)
- F1. The Reporting Person is a managing director of Goldman Sachs & Co LLC ("GS&Co"), a subsidiary of The Goldman Sachs Group Inc. ("GS Group"). GS Group is the direct owner of GS&Co. and an indirect owner of Goldman Sachs Asset Management, L.P. ("GSAM LP"). GS&Co. is the manager of Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock of the Issuer. GSAM LP is the investment manager of WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly owns 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock of the Issuer,... [continued in footnote 2]
- F2. [continued from footnote 1]... West Street Life Sciences I, L.P. ("WSLS I"), which owns 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock of the Issuer, WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which owns 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock of the Issuer, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock of the Issuer.
- F3. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Underlying common shares from Series B Preferred Stock: 1,957,140 shares
Underlying common shares from Series C Preferred Stock: 478,501 shares
Exercise/conversion price: 0.0000
3 metrics
Underlying common shares from Series B Preferred Stock
1,957,140 shares
Indirect holdings reported by Colin Walsh, underlying security shares
Underlying common shares from Series C Preferred Stock
478,501 shares
Indirect holdings reported by Colin Walsh, underlying security shares
Exercise/conversion price
0.0000
Conversion or exercise price for both Series B and Series C Preferred Stock
Key Terms
Series B Preferred Stock, Series C Preferred Stock, beneficial ownership, pecuniary interest
4 terms
Series B Preferred Stock financial
"Series B Preferred Stock convertible into 1,957,140 shares of common stock"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Series C Preferred Stock financial
"Series C Preferred Stock convertible into 478,501 shares of common stock"
A Series C preferred stock is a specific class of ownership issued during a later funding round that gives holders priority over common shareholders for getting paid and receiving dividends, like having a reserved lane in traffic when money is distributed. It often includes agreed rights such as a fixed payout, protection against dilution, and the option to convert into common shares, so investors treat it as a mix of safety and upside potential.
beneficial ownership financial
"disclaims beneficial ownership of the securities reported herein except to the extent"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of the Reporting Person's pecuniary interest therein, if any"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Colin Walsh report owning in Attovia Therapeutics (ATTO) on this Form 3?
Colin Walsh reported indirect holdings of Series B and Series C Preferred Stock of Attovia Therapeutics, convertible into 1,957,140 and 478,501 common shares, respectively, through Goldman Sachs–affiliated investment entities.
Are Colin Walsh’s Attovia (ATTO) holdings direct or indirect?
The Form 3 shows Walsh’s Attovia interests as indirect holdings. The Series B and Series C Preferred Stock positions are held through Goldman Sachs–affiliated investment vehicles rather than in his personal name.
Does Colin Walsh disclaim beneficial ownership of his reported Attovia (ATTO) securities?
Yes. A footnote states Walsh disclaims beneficial ownership of the reported securities except to the extent of any pecuniary interest, and clarifies that the filing should not be deemed an admission of beneficial ownership.
Which entities are associated with Colin Walsh’s Attovia (ATTO) preferred stock holdings?
Footnotes explain that the reported Series B and Series C Preferred Stock are held by Goldman Sachs–affiliated entities, including Goldman Sachs & Co. LLC and various Broad Street and West Street Life Sciences investment vehicles.
AI-generated analysis. How Rhea-AI works. Not financial advice.
